SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new research highlighting the potential of its ...
For Maze’s MZE829 program, Guggenheim increased its probability of success estimate to 30% from 20% for diabetic AMKD (APOL1-mediated kidney disease), maintaining the same 30% probability for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback